Pharmaceutical composition, external preparation and preparation method and application thereof
By using the combination of pharmaceutical active ingredients, diethylene glycol monoethyl ether and polyethylene glycol 400 in the topical preparation, the formulation is optimized to improve permeability and retention capacity, and the problem of insufficient retention and permeability of existing topical preparations is solved. Achieve better therapeutic effects and safety.
Patent Information
- Application Number
- CN202410648890.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-05-24
- Filing Date
- 2024-05-23
- Publication Date
- 2024-11-26
AI Technical Summary
The lack of skin retention and permeability of existing topical preparations leads to poor treatment effects and risks of systemic side effects.
Using pharmaceutical compositions, including pharmaceutical active ingredients, diethylene glycol monoethyl ether and polyethylene glycol 400, to improve the permeability and retention of the drug by optimizing their mass ratio and formulation. ability to reduce systemic side effects.
The rapid penetration of the stratum corneum of the drug is achieved, the local concentration and therapeutic effect are improved, the safety risks are reduced, and the stability and crystal-free properties of the preparation are maintained.
Smart Images

Figure CN119015284A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to a pharmaceutical composition, an external preparation and a preparation method and application thereof. Background Art
[0002] Cytokines of skin immune diseases activate JAKs kinases in multiple cells through their respective receptors, regulating the differentiation, proliferation and secretion inhibition of related immune cells. The JAK / STAT pathway can inhibit the activation of immune cells and T cell-mediated inflammation, making it a popular target for inflammatory diseases. JAnus kinases are cytoplasmic protein tyrosine family kinases including JAK1, JAK2, JAK3 and TYK2.
[0003] Currently, there are a variety of JAK inhibitors used to treat skin lesions, including oral preparations such as Tofacitinib, Deucravacitinib, Baricitinib, and Ruxolitinib. The oral Tofacitinib, which has completed Phase III clinical trials, has been suspended due to the FDA's request to continue to provide safety data, and systemic medication may cause serious adverse reactions. Topical administration of active pharmaceutical ingredients has become the preferred method of administration for the treatment of skin diseases such as rheumatoid arthritis, psoriasis, and alopecia areata.
[0004] However, the skin retention and permeability of current topical preparations containing active pharmaceutical ingredients need to be improved during application. Summary of the invention
[0005] The technical problem to be solved by the present invention is to overcome the defects of the existing external preparations in terms of small skin retention and poor permeability, and provide a pharmaceutical composition, external preparation and its preparation method and application. The external preparation prepared by the pharmaceutical composition provided by the present invention has stable properties, will not crystallize, has a good skin feel, can promote the rapid penetration of drugs into the stratum corneum, has good epidermal and dermal retention capacity, targets the delivery of drugs to the skin, can reduce systemic side effects and achieve a higher local concentration, has a strong therapeutic effect, stability and can reduce safety risks.
[0006] The present invention solves the above technical problems through the following technical solutions.
[0007] The present invention provides a pharmaceutical composition, which comprises a pharmaceutical active ingredient, diethylene glycol monoethyl ether and polyethylene glycol 400 (PEG400); the pharmaceutical composition does not contain water;
[0008] Wherein, the mass ratio of the diethylene glycol monoethyl ether to the polyethylene glycol 400 is 1:(0.5-4.0); the active pharmaceutical ingredient has the structural formula (I):
[0009]
[0010] In the present invention, the active pharmaceutical ingredient having the structural formula (I) can be prepared by the preparation method disclosed in Example 113 of CN113227074A.
[0011] In the present invention, the dosage of the active pharmaceutical ingredient may be 0.001% to 10%, for example 0.1%, 0.3%, 0.6%, 1.0%, 1.2%, 1.5% or 2.0%, where % refers to the mass percentage of the active pharmaceutical ingredient in the pharmaceutical composition.
[0012] In the present invention, diethylene glycol monoethyl ether not only has the function of increasing or accelerating the penetration of drugs through the skin, but also has the function of serving as a solvent to dissolve compounds.
[0013] In the present invention, the dosage of diethylene glycol monoethyl ether can be 15-40%, for example, 20.0%, 23.0% or 33.8%, where % refers to the mass percentage of diethylene glycol monoethyl ether in the pharmaceutical composition.
[0014] In the present invention, the mass ratio of the pharmaceutically active ingredient to the diethylene glycol monoethyl ether is preferably 1:(10.0-250.0), for example 1:13.33, 1:15.33, 1:16.67, 1:16.90, 1:20, 1:23, 1:33.33, 1:66.67, 1:76.67, 1:200 or 1:230.
[0015] In the present invention, the dosage of polyethylene glycol 400 can be 30-55%, for example, 30.4%, 38.8%, 45.3%, 52.5% or 52.9%, where % refers to the mass percentage of polyethylene glycol 400 in the pharmaceutical composition.
[0016] In the present invention, the mass ratio of the diethylene glycol monoethyl ether to the polyethylene glycol 400 is preferably 1:(0.5-3.0), for example, 1:0.90, 1:1.94, 1:1.97, 1:2.63 or 2.65.
[0017] In the present invention, preferably, the pharmaceutical composition further comprises polyethylene glycol 3350 (PEG3350).
[0018] Wherein, when the pharmaceutical composition includes polyethylene glycol 3350, the amount of polyethylene glycol 3350 can be 25.0-50%, preferably 25.0-45.0%, for example, 25.8%, 26.3%, 26.5%, 27%, 27.2%, 30%, 30.5%, 31.2%, 31.4%, 33.8% or 40%.
[0019] Wherein, when the pharmaceutical composition includes polyethylene glycol 3350, the mass ratio of the diethylene glycol monoethyl ether to the polyethylene glycol 3350 can be 1:(0.5-3.6), preferably 1:(0.5-3.0), for example, 1:1.00, 1:1.29, 1:1.30, 1:1.32, 1:1.33, 1:1.35, 1:1.36, 1:1.37 or 1:2.00.
[0020] In the present invention, preferably, the pharmaceutical composition further comprises one or more of an antioxidant, a preservative, a hardener and a humectant.
[0021] The antioxidant may be an aromatic amine antioxidant, such as butylated hydroxytoluene.
[0022] The amount of the antioxidant may be 0.05-0.2%, for example 0.1%.
[0023] Wherein, the preservative may be one or more of methylparaben, sorbic acid and salts thereof, such as methylparaben.
[0024] The amount of the preservative may be 0.05-0.2%, for example 0.1%.
[0025] Wherein, the hardener may be one or more of paraffin, beeswax, cetostearyl alcohol, white vaseline and glyceryl mono- and distearate.
[0026] The amount of the hardener may be 5-40%, for example 9.8%, 22.1%, 30.65% or 37.6%.
[0027] The moisturizing agent may be one or more of glycerin, light liquid paraffin, soybean oil, medium chain triglycerides, sodium hyaluronate, urea, propylene glycol, butylene glycol, panthenol, sodium pyrrolidone carboxylate and trehalose, preferably propylene glycol.
[0028] The amount of the moisturizer may be 2-80%, for example, 5.0%, 9.0%, 20.0%, 37.5% or 77.5%.
[0029] In the present invention, the pharmaceutical composition may be in the form of a solution, a gel, an ointment or a cream.
[0030] In the present invention, when the pharmaceutical composition is a semisolid, such as a cream, the particle size of the active pharmaceutical ingredient may be less than 180 μm.
[0031] In the present invention, after the components in the pharmaceutical composition are mixed, there is no crystallization phenomenon and a single-phase system is formed.
[0032] In some preferred embodiments, the pharmaceutical composition comprises the above-mentioned active pharmaceutical ingredient, diethylene glycol monoethyl ether, polyethylene glycol 400 and polyethylene glycol 3350; the pharmaceutical composition does not contain water;
[0033] Wherein, the mass ratio of the diethylene glycol monoethyl ether to the polyethylene glycol 400 is 1:(0.5-4.0); the mass ratio of the diethylene glycol monoethyl ether to the polyethylene glycol 3350 is 1:(0.5-3.6).
[0034] In some preferred embodiments, the pharmaceutical composition comprises the above-mentioned active pharmaceutical ingredient, diethylene glycol monoethyl ether, polyethylene glycol 400 and polyethylene glycol 3350; the pharmaceutical composition does not contain water;
[0035] Wherein, the mass ratio of the diethylene glycol monoethyl ether to the polyethylene glycol 400 is 1:(0.5-3.0); the mass ratio of the diethylene glycol monoethyl ether to the polyethylene glycol 3350 is 1:(0.5-3.0).
[0036] In some preferred embodiments, the pharmaceutical composition comprises, by weight percentage:
[0037]
[0038] In some preferred embodiments, the pharmaceutical composition comprises, by weight percentage:
[0039]
[0040] The present invention also provides an external preparation, which comprises the above-mentioned pharmaceutical composition. In the present invention, the external preparation can be a liquid preparation or a semi-solid preparation.
[0041] Wherein, the liquid preparation can be a liniment or a tincture.
[0042] Wherein, the semi-solid preparation can be a cream, an organogel, an ointment or a paste. In some preferred embodiments, the formula of the ointment comprises, by weight percentage:
[0043] Preferably, the ointment comprises, by weight percentage:
[0044]
[0045] More preferably, the ointment comprises, by weight percentage:
[0046]
[0047] More preferably, the ointment comprises, by weight percentage:
[0048]
[0049] More preferably, the ointment comprises, by weight percentage:
[0050] More preferably, the ointment comprises, by weight percentage:
[0051] Preferably, the ointment comprises, by weight percentage:
[0052] More preferably, the ointment comprises, by weight percentage:
[0053] More preferably, the ointment comprises, by weight percentage:
[0054]
[0055]
[0056] More preferably, the ointment comprises, by weight percentage:
[0057] More preferably, the ointment comprises, by weight percentage:
[0058] Preferably, the ointment comprises, by weight percentage:
[0059] More preferably, the ointment comprises, by weight percentage:
[0060]
[0061]
[0062] More preferably, the ointment comprises, by weight percentage:
[0063] More preferably, the ointment comprises, by weight percentage:
[0064] More preferably, the ointment comprises, by weight percentage:
[0065] Preferably, in terms of weight percentage, the ointment comprises:
[0066]
[0067]
[0068] Preferably, in terms of weight percentage, the ointment comprises:
[0069]
[0070] The present invention also provides a method for preparing the above-mentioned pharmaceutical composition, which comprises the following steps:
[0071] (1) Preparing API solution: mixing the active pharmaceutical ingredient, diethylene glycol monoethyl ether and polyethylene glycol 400 at 50-80° C. until dissolved;
[0072] (2) Preparation of matrix solution: Heat polyethylene glycol 3350 at 50-80°C until it melts;
[0073] (3) Preparation of ointment: Mix the API solution and the base solution under stirring conditions.
[0074] In step (1), the mixing temperature is preferably 50°C or 80°C.
[0075] In step (2), preferably, the raw material further comprises one or more of an antioxidant, a preservative, a hardener and a humectant.
[0076] In step (2), preferably, the raw material also includes diethylene glycol monoethyl ether.
[0077] Among them, preferably, when the raw material in step (2) includes diethylene glycol monoethyl ether, the amount of diethylene glycol monoethyl ether in step (1) is 2 / 3 of the prescribed amount, and the amount of diethylene glycol monoethyl ether in step (2) is 1 / 3 of the prescribed amount.
[0078] In a preferred embodiment, the preparation of the matrix solution comprises the following steps: adding methylparaben to diethylene glycol monoethyl ether, stirring at 50-80° C. until completely dissolved; then adding butylated hydroxytoluene and polyethylene glycol 3350, stirring until melted.
[0079] In step (2), the heating temperature is preferably 50°C or 80°C.
[0080] In step (3), the stirring speed may be conventional in the art, preferably 315 rpm.
[0081] In step (3), the stirring time can be conventional in the art, preferably 10 to 15 minutes.
[0082] In step (3), the mixing temperature is preferably 50-60°C.
[0083] In step (3), after the mixing is completed, a cooling operation may also be included.
[0084] Wherein, the cooling can be carried out by circulating water cooling.
[0085] The present invention also provides an application of the above-mentioned pharmaceutical composition or external preparation in preparing a drug for treating autoimmune diseases.
[0086] In the present invention, the autoimmune disease can be arthritis, rheumatoid arthritis, psoriasis, psoriasis, osteoarthritis, regional suppurative disease, ankylosing spondylitis, autoimmune eye disease, dry eye, atopic dermatitis, contact dermatitis, systemic lupus erythematosus or alopecia areata.
[0087] On the basis of being in accordance with the common sense in the art, the above-mentioned preferred conditions can be arbitrarily combined to obtain the preferred embodiments of the present invention.
[0088] In the present invention, except for the active pharmaceutical ingredients, all the reagents and raw materials used are commercially available.
[0089] The positive and progressive effects of the present invention are:
[0090] The external preparation made from the pharmaceutical composition provided by the present invention has stable properties, does not crystallize, has a good skin feel, can promote the rapid penetration of drugs into the stratum corneum, and has good epidermal and dermal retention capacity, and can deliver drugs to the skin in a targeted manner, thereby reducing systemic side effects and achieving a higher local concentration, having a strong therapeutic effect, stability, and reducing safety risks. BRIEF DESCRIPTION OF THE DRAWINGS
[0091] Figure 1 The microscopic observation results of the ointment prepared by 3A in Example 3. Figure 1 Part (a) of is the initial condition, Figure 1 Part (b) is accelerated conditions for 6 months.
[0092] Figure 2 The following are the microscopic observation results of the cream prepared in Example 7 under initial conditions.
[0093] Figure 3 The microscopic observation results of the hydrogel prepared in Example 10 under initial conditions.
[0094] Figure 4 The microscopic observation results of the organogel prepared in Example 12 under the initial conditions. Figure 4 Part (a) of is the initial condition, Figure 4 Part (b) is accelerated conditions for 6 months.
[0095] Figure 5 The following are the results of microscopic observation of the ointment prepared in Example 13.
[0096] Figure 6 This is a square root curve of the cumulative amount of drug released per unit area-time in Effect Example 2.
[0097] Figure 7 This is the release rate-specification curve in Effect Example 2. DETAILED DESCRIPTION
[0098] The present invention is further described below by way of examples, but the present invention is not limited to the scope of the examples. The experimental methods in the following examples without specifying specific conditions are carried out according to conventional methods and conditions, or selected according to the product specifications.
[0099] In a specific embodiment of the present invention, the pharmaceutical active ingredient having structural formula (I) is prepared by the preparation method disclosed in Example 113 of CN113227074A.
[0100] Example 1 Ointment
[0101] The ointment prescription is shown in Table 1 below.
[0102] Table 1
[0103] serial number 1A 1B 1C 1D effect Active ingredient of drug / % 0.6 1.2 1.2 2.0 API Diethylene glycol monoethyl ether / % 20.0 20.0 20.0 33.8 Penetration enhancers, solvents Polyethylene glycol 400 / % 52.9 52.5 38.8 30.4 Penetration enhancers, solvents Polyethylene glycol 3350 / % 26.5 26.3 40.0 33.8 Ointment base total / % 100.0 100.0 100.0 100.0 -
[0104] The preparation process is as follows:
[0105] (1) Preparation of API solution: Weigh the prescribed amount of active ingredient, diethylene glycol monoethyl ether (Transcutol P) and polyethylene glycol 400 (PEG 400) into a container, heat in a water bath at 80°C, and stir until completely dissolved.
[0106] (2) Preparation of matrix solution: Take the prescribed amount of polyethylene glycol 3350 (PEG 3350), heat it in a water bath at 80°C, and stir until it melts.
[0107] (3) Preparation of ointment: The molten matrix solution was slowly added to the API solution under stirring. The mixture was stirred for 10 min at a speed of 315 rpm and then cooled to form an ointment.
[0108] Example 2 Ointment
[0109] The ointment prescription is shown in Table 2 below.
[0110] Table 2
[0111] serial number 2A 2B 2C 2D effect Active ingredient of drug / % 0.1 0.3 1.0 1.5 API Diethylene glycol monoethyl ether / % 20.0 20.0 20.0 20.0 Penetration enhancers, solvents Polyethylene glycol 400 / % 52.5 52.5 52.5 52.5 Penetration enhancers, solvents Polyethylene glycol 3350 / % 27.2 27.0 26.3 25.8 Ointment base Butylated hydroxytoluene / % 0.1 0.1 0.1 0.1 Antioxidants Methylparaben / % 0.1 0.1 0.1 0.1 preservative Total amount / % 100.0 100.0 100.0 100.0 -
[0112] The preparation process is as follows:
[0113] (1) Preparation of API solution: Weigh the prescribed amount of the active ingredient API, diethylene glycol monoethyl ether (Transcutol P) and polyethylene glycol 400 (PEG 400) into a container, heat in a water bath at 80°C, and stir until the API is completely dissolved.
[0114] (2) Preparation of matrix solution: Take the prescribed amount of polyethylene glycol 3350 (PEG 3350), heat it in a water bath at 80°C, and stir until it melts.
[0115] (3) Preparation of ointment: The molten matrix solution was slowly added to the API solution under stirring. After addition, the solution was stirred and cooled to 35°C at a stirring speed of 310 rpm. Finally, the solution was allowed to stand and cool to room temperature.
[0116] Example 3 Ointment
[0117] The ointment prescription is shown in Table 3 below.
[0118] Table 3
[0119] serial number 3A 3B 3C 3D effect Active ingredient of drug / % 0.1 0.3 1.0 1.5 API Diethylene glycol monoethyl ether / % 23.0 23.0 23.0 23.0 Penetration enhancers, solvents Polyethylene glycol 400 / % 45.3 45.3 45.3 45.3 Penetration enhancers, solvents Polyethylene glycol 3350 / % 31.399 31.1993 30.49975 30.0 Ointment base Butylated hydroxytoluene / % 0.1 0.1 0.1 0.1 Antioxidants Methylparaben / % 0.1 0.1 0.1 0.1 preservative Tartrazine / % 0.001 0.0007 0.00025 0 pigment Total amount / % 100.0 100.0 100.0 100.0 -
[0120] The preparation process is as follows:
[0121] (1) Preparation of API solution: Weigh the prescribed amount of the active ingredient drug substance, diethylene glycol monoethyl ether (Transcutol P) and 2 / 3 of the prescribed amount of polyethylene glycol 400 (PEG 400) into a container, heat at 50°C to 60°C, and stir until completely dissolved.
[0122] (2) Preparation of matrix solution: Weigh the prescribed amount of methylparaben and add it to 1 / 3 of the prescribed amount of PEG400, stirring at 70±5°C to completely dissolve the methylparaben; then add the prescribed amount of polyethylene glycol 3350 (PEG 3350) and butylated hydroxytoluene, stirring at 70±5°C to completely melt the PEG3350 and butylated hydroxytoluene. Cool down to 50-60°C.
[0123] (3) Preparation of ointment: Pour the API solution into the matrix solution while stirring at 50-60°C. After stirring for 15 min, add tartrate to adjust the color and cool the solution with stirring at room temperature.
[0124] Take a clean slide, take an appropriate amount of sample 3A (about 0.01g each time) and apply it on the slide, cover it with a cover glass, press the cover glass gently, and first observe the ointment (initial condition and accelerated condition 40℃, 75%RH for 6 months) under the conditions of eyepiece 10X, objective lens 40X, and polarized light 300°. The results are as follows Figure 1 Part (a) and Figure 1 As shown in part (b), the ointment has no crystallization phenomenon.
[0125] Example 4 Ointment
[0126] The ointment prescription is shown in Table 4 below.
[0127] Table 4
[0128] serial number 4A 4B 4C 4D effect Active ingredient of drug / % 0.8 1.1 2.0 1.6 API Diethylene glycol monoethyl ether / % 14.5 20.1 20.0 29.0 Penetration enhancers, solvents Polyethylene glycol 400 / % 12.5 17.34 24.0 / Penetration enhancers, solvents paraffin / % / / / 5.0 Hardener beeswax / % / 30.65 / / Hardener Cetostearyl alcohol / % / / 9.8 / Hardener White petrolatum / % 22.1 / / 22.6 Hardener Glyceryl mono- and distearate / % / / / 10.0 Hardener Propylene glycol / % / / 20.0 9.0 Solvent, humectant Polyethylene glycol 3350 / % 50.0 30.65 24.0 22.3 Ointment base Butylated hydroxytoluene / % 0.05 0.07 0.1 0.1 Antioxidants Methylparaben / % 0.05 0.09 0.1 0.1 preservative total / % 100.0 100.0 100.0 100.0 -
[0129] The preparation process is as follows:
[0130] (1) Preparation of API solution: Weigh the prescribed amount of the active ingredient drug substance, diethylene glycol monoethyl ether (Transcutol P) and polyethylene glycol 400 (PEG 400) into a container, heat in a water bath at 80°C, and stir until completely dissolved.
[0131] (2) Preparation of matrix solution: Take the prescribed amount of polyethylene glycol 3350 (PEG 3350), hardener, butylated hydroxytoluene, methylparaben and propylene glycol, heat them in a water bath at 80° C., and stir until they are melted.
[0132] (3) Preparation of ointment: The molten matrix solution was slowly added to the API solution under stirring. The mixture was stirred for 10 min at a speed of 315 rpm and then allowed to cool to room temperature.
[0133] Example 5 Ointment
[0134] The ointment prescription is shown in Table 5 below.
[0135] Table 5
[0136] serial number 5A 5B 5C 5D effect Active ingredient of drug / % 1.5 1.5 1.5 1.5 API Diethylene glycol monoethyl ether / % 23.0 20.0 20.0 20.0 Penetration enhancers, solvents Polyethylene glycol 400 / % 45.5 48.5 43.5 52.7 Penetration enhancers, solvents Polyethylene glycol 3350 / % 30.0 30.0 35.0 25.8 Ointment base total / % 100.0 100.0 100.0 100.0 -
[0137] The preparation process is as follows:
[0138] (1) Preparation of API solution: Weigh the prescribed amount of the active ingredient drug substance, diethylene glycol monoethyl ether (Transcutol P) and polyethylene glycol 400 (PEG 400) into a container, heat in a water bath at 80°C, and stir until completely dissolved.
[0139] (2) Preparation of matrix solution: Take the prescribed amount of polyethylene glycol 3350 (PEG 3350), heat it in a water bath at 80°C, and stir until it melts.
[0140] (3) Preparation of ointment: The molten matrix solution was slowly added to the API solution under stirring. The mixture was stirred for 10 min at a speed of 315 rpm and then allowed to cool to room temperature.
[0141] Example 6 Ointment
[0142] The ointment prescription is shown in Table 6 below.
[0143] Table 6
[0144]
[0145]
[0146] The preparation process is as follows:
[0147] (1) Preparation of API solution: Weigh the prescribed amount of the active ingredient drug substance, diethylene glycol monoethyl ether (Transcutol P), polyethylene glycol 600 (PEG 600) and moisturizer into a container, heat in a water bath at 80°C, and stir until completely dissolved.
[0148] (2) Preparation of matrix solution: Take the prescribed amount of polyethylene glycol 3350 (PEG 3350), heat it in a water bath at 80°C, and stir until it melts.
[0149] (3) Preparation of ointment: The molten matrix solution was slowly added to the API solution under stirring. The mixture was stirred for 10 min at a speed of 315 rpm and then cooled to form an ointment.
[0150] Example 7 Cream
[0151] The cream prescription is shown in Table 7 below.
[0152] Table 7
[0153] serial number 7A effect Active ingredient of drug / % 0.6 API Diethylene glycol monoethyl ether / % 10.0 Penetration enhancers, solvents Propylene glycol / % 2.00 Penetration enhancers, solvents Macrogol-7 stearate / % 8.00 Emulsifier Oleoyl polyoxyethylene glyceride / % 2.00 Emulsifier Glyceryl mono- and distearate / % 1.5 Oil base, thickener Medium chain triglycerides / % 5.00 Oily base Purified water / % 70.9 Aqueous matrix total / % 100.0 -
[0154] The preparation process is as follows:
[0155] (1) Preparation of API solution: Add the prescribed amount of the active ingredient API into diethylene glycol monoethyl ether (Transcutol P), heat to 80°C to dissolve the API, then add the prescribed amount of propylene glycol, and stir for 3 min to mix evenly.
[0156] (2) Preparation of oil phase: Weigh the prescribed amount of polyethylene glycol-7 stearate, oleoyl polyoxyethylene glyceride, mono- and distearic glyceryl, and medium-chain triglycerides, and heat at 80° C. until melted.
[0157] (3) Preparation of cream: Add the API solution to the prepared oil phase under stirring, start homogenization (speed 15000 rpm), slowly add the oil phase containing the API into 80°C purified water, and homogenize for 10 min.
[0158] The obtained cream has a uniform texture. Sample 7A was observed under the initial conditions according to the method in Example 3. The results are as follows: Figure 2 As shown, the emulsion droplets in the cream are uniform, and the particle size is about 10 to 30 μm.
[0159] Example 8 Cream
[0160] The cream prescription is shown in Table 8 below.
[0161] Table 8
[0162] serial number 8A 8B 8C 8D effect Active ingredient of drug / % 0.2 0.2 0.1 0.2 API Diethylene glycol monoethyl ether / % 10.0 10.0 10.0 10.0 Penetration enhancers, solvents Polyethylene glycol 400 / % 8.0 8.0 8.0 8.0 Penetration enhancers, solvents Polyethylene glycol-7-stearate / % 10.0 10.0 10.0 10.0 Emulsifier Oleoyl polyoxyethylene glyceride / % 4.0 4.0 4.0 4.0 Emulsifier Glyceryl mono- and distearate / % 3.0 3.0 3.0 3.0 Oil base, thickener Medium chain triglycerides / % 5.0 5.0 5.0 5.0 Oily base Hydroxypropyl methylcellulose / % 3.0 5.0 3.0 / Aqueous matrix Carbomer / % / / / 0.2 Aqueous matrix Purified water / % 56.8 54.8 56.9 59.6 Aqueous matrix total / % 100.0 100.0 100.0 100.0 -
[0163] The preparation process is as follows:
[0164] (1) Preparation of API solution: Dissolve the prescribed amount of the active ingredient in a mixture of diethylene glycol monoethyl ether (Transcutol P) and polyethylene glycol 400 (PEG 400) at 80°C.
[0165] (2) Preparation of oil phase: Weigh the prescribed amount of polyethylene glycol-7-stearate, oleoyl polyoxyethylene glyceride, mono- and distearic glyceryl, and medium-chain triglycerides, and heat at 80° C. until melted.
[0166] (3) Preparation of aqueous phase:
[0167] Hydroxypropyl methylcellulose solution (8A, 8B, 8C): Weigh the prescribed amount of purified water, slowly add the hydropropyl methylcellulose while stirring, and stir until the hydropropyl methylcellulose is completely dissolved;
[0168] Carbomer solution (8D): Dissolve the prescribed amount of carbomer in purified water.
[0169] (4) Preparation of cream:
[0170] a. Preparation of cream (Batch 8A / Batch 8B): Mix the oil phase and API solution with magnetic stirring in a water bath at 80°C for 5 minutes. When the temperature drops to 50°C, add the aqueous phase (hydroxypropyl methylcellulose solution), stir vigorously for 5 minutes (stirring speed: 520 rpm), and let it stand to cool.
[0171] b. Preparation of cream (batch 8C): The oil phase and API solution were mixed with magnetic stirring in a water bath at 80°C for 10 min. When the temperature dropped to 50°C, the aqueous phase (hydroxypropyl methylcellulose solution) was added and homogenization was started (homogenization speed 9.0±0.2 Kr / min) for 5 min, and the temperature was dropped to 30°C (homogenization speed 8.8 Kr / min).
[0172] c. Preparation of cream (8D batch): The oil phase and API solution were mixed with magnetic stirring in a water bath at 80°C for 10 min, added to the aqueous phase (carbomer solution), stirred vigorously for 5 min (360 rpm), and cooled to 30°C with stirring (200 rpm).
[0173] Example 9 Cream
[0174] The cream prescription is shown in Table 9 below.
[0175] Table 9
[0176] serial number 9A 9B 9C effect Active ingredient of drug / % 1.5 1.5 1.5 API Diethylene glycol monoethyl ether / % 30.0 30.0 30.0 Penetration enhancers, solvents Polyethylene glycol 400 / % 15.0 15.0 15.0 Penetration enhancers, solvents Polyethylene glycol-7-stearate / % 12.0 12.0 12.0 Emulsifier Cetyl alcohol / % 3.0 / / Oil base, thickener Monoglyceride / % / 3.0 / Oil base, thickener Glyceryl mono- and distearate / % / / 3.0 Oil base, thickener Light liquid paraffin / % 2.0 2.0 2.0 Oil base, thickener Medium chain triglycerides / % 6.0 6.0 6.0 Oily base Tween 80 / % 1.0 1.0 1.0 Surfactants Ethyl paraben / % 0.1 0.1 0.1 preservative Purified water / % 29.4 29.4 29.4 Aqueous matrix total / % 100.0 100.0 100.0 -
[0177] The preparation process is as follows:
[0178] (1) Preparation of API solution: Dissolve the prescribed amount of the active ingredient in a mixture of diethylene glycol monoethyl ether (Transcutol P) and polyethylene glycol 400 (PEG 400).
[0179] (2) Preparation of oil phase: Weigh the prescribed amount of polyethylene glycol-7-stearate, hexadecanol (9A), monoglyceride (9B), mono- and distearic glyceride (9C), light liquid paraffin, and medium-chain triglyceride, and heat them in a water bath at 80° C. to melt into a liquid mixture.
[0180] (3) Prepare the aqueous phase: Dissolve the prescribed amount of Tween 80 and ethylparaben in purified water at 70°C.
[0181] (4) Preparation of cream: Mix the oil phase and API solution with magnetic stirring in a 70°C water bath for 5 min. Add the water phase at 70°C, shear at high speed for 5 min, and take an appropriate amount and place it in an EP tube for cooling.
[0182] Example 10 Hydrogel
[0183] The hydrogel formulation is shown in Table 10 below.
[0184] Table 10
[0185] serial number 10A effect Active ingredient of drug / % 0.2 API Diethylene glycol monoethyl ether / % 3.3 Penetration enhancers, solvents Polyethylene glycol 400 / % 2.7 Penetration enhancers, solvents Carbomer / % 1.0 Gel Matrix Purified water / % 92.8 Gel Matrix 2M sodium hydroxide solution / % qs pH Adjusters total / % 100.0 -
[0186] Note: "qs" in the table means trace amount.
[0187] The preparation process is as follows:
[0188] (1) Preparation of API solution: Add a mixture of diethylene glycol monoethyl ether (Transcutol P) and polyethylene glycol 400 (PEG 400) to the prescribed amount of the API and stir at 80°C for 10 min to dissolve the API.
[0189] (2) Preparation of carbomer solution: Weigh the prescribed amount of carbomer and completely dissolve it in purified water.
[0190] (3) Preparation of gel: Add the API solution to the prepared carbomer solution while stirring (stirring speed 205 rpm), add a trace amount of 2M sodium hydroxide solution, continue stirring for 3 minutes after all the solution is added, make up the remaining water in the prescription and stir for 5 minutes (stirring speed 900 rpm).
[0191] The sample 10A was observed microscopically under the initial conditions according to the method in Example 3. The results are as follows: Figure 3 As shown. It shows that the hydrogel has a small amount of crystallization under the initial conditions, and the crystal size is about 15μm.
[0192] Example 11 Hydrogel
[0193] The hydrogel formulation is shown in Table 11 below.
[0194] Table 11
[0195]
[0196]
[0197] The preparation process is as follows:
[0198] (1) Preparation of API solution: Weigh the prescribed amount of the active ingredient, add diethylene glycol monoethyl ether (or dimethyl sulfoxide) and PEG 400, and stir at 50°C for 10 min to dissolve the API.
[0199] (2) Preparation of carbomer solution: Weigh the prescribed amount of carbomer and completely dissolve it in purified water.
[0200] (3) Preparation of gel: Add the API solution to the prepared carbomer solution while stirring (stirring speed 205 rpm). Continue stirring for 3 minutes after all the solution is added. Make up the remaining water in the prescription and stir for 5 minutes (stirring speed 900 rpm).
[0201] Example 12 Organogel
[0202] The organogel formulation is shown in Table 12 below.
[0203] Table 12
[0204] serial number 12A 12B 12C effect Active ingredient of drug / % 1.5 1.5 1.5 API Diethylene glycol monoethyl ether / % 20.0 20.0 20.0 Penetration enhancers, solvents Polyethylene glycol 400 / % 77.5 40.0 / Penetration enhancers, solvents Propylene glycol / % / 37.5 77.5 Humectant, solvent Carbomer / % 1.0 1.0 1.0 Gel Matrix total / % 100.0 100.0 100.0 -
[0205] The preparation process is as follows:
[0206] (1) Preparation of API solution: Weigh the prescribed amount of the active ingredient API and diethylene glycol monoethyl ether (Transcutol P) and stir at 50°C for 20 min.
[0207] (2) Preparation of carbomer solution: Weigh the prescribed amount of carbomer and completely swell it with the prescribed amount of polyethylene glycol 400 or propylene glycol.
[0208] (3) Preparation of gel: Add the API solution to the prepared carbomer solution while stirring (stirring speed 205 rpm). After all the solution is added, continue stirring for 3 min (stirring speed 900 rpm).
[0209] The sample 12A (initial condition and accelerated condition 40°C, 75% RH for 6 months) was observed by microscopy according to the method in Example 3. Figure 4 Part (a) and Figure 4 As shown in part (b), the organogel has no crystallization phenomenon.
[0210] Example 13 Liniment
[0211] The ointment prescription is shown in Table 13 below.
[0212] Table 13
[0213] serial number 13A 13B 13C effect Active ingredient of drug / % 2.0 2.0 2.0 API Diethylene glycol monoethyl ether / % 20.0 20.0 20.0 Penetration enhancers, solvents Propylene glycol / % / 30.0 / Penetration enhancers, solvents Ethanol / % / / 60.0 Penetration enhancers, solvents Polyethylene glycol 400 / % 78.0 48.0 18.0 Penetration enhancers, solvents total / % 100.0 100.0 100.0 -
[0214] The preparation process is as follows:
[0215] Weigh the prescribed amount of active pharmaceutical ingredients and permeation enhancer, mix the prescribed amount of permeation enhancer, add the active pharmaceutical ingredients, and stir at 50±5° C. to completely dissolve them. The liniment in this embodiment is in a solution state.
[0216] The sample 13A was observed microscopically under the initial conditions according to the method in Example 3. Figure 5 As shown, the visual field is free of crystals.
[0217] Comparative Example 1
[0218] Compared with Example 1, the difference is that the prescription is as shown in Table 14 below:
[0219] Table 14
[0220] serial number 1a effect Active ingredient of drug / % 0.6 API Diethylene glycol monoethyl ether / % 10.0 Penetration enhancers, solvents Polyethylene glycol 400 / % 39.4 Penetration enhancers, solvents Polyethylene glycol 3350 / % 50.0 Ointment base total / % 100.0 -
[0221] Comparative Example 2
[0222] Compared with sample 1A of Example 1, the difference is that the active ingredient of the drug is replaced with tofacitinib citrate (batch number: HY-170-35-20200327; purchased from: Shanghai Haoyuan Pharmaceutical Co., Ltd.), and the prepared sample is numbered 2a.
[0223] Comparative Example 3
[0224] The active ingredient of the drug was formulated in 50% PEG400, 10% diethylene glycol monoethyl ether and 40% PEG3350 (50% aqueous solution) to prepare a sample numbered 3a.
[0225] Effect Example 1 Microscopic Observation Results
[0226] Microscopic results showed that Figure 1 Part (a) of Figure 4 Part (a) and Figure 5 It can be seen that the ointment, organogel and liniment showed no crystallization under the initial conditions. Figure 1 From part (b), we can see that the ointment is stable for a long time without crystallization, and the product has a uniform texture and good skin feel. Figure 4 From part (b), we can see that no obvious large crystals are precipitated during the stability storage of the organogel, and the particle size is no more than 180 μm. Figure 2 and Figure 3 It can be seen that there is no obvious large-particle crystal precipitation in the cream and hydrogel under the initial conditions, and the particle size is less than 180μm.
[0227] Effect Example 2 Ointment in vitro release data
[0228] The release amount was calculated by the external standard method. The test method for in vitro release is shown in Table 15 below:
[0229] Table 15
[0230]
[0231] Samples 3A, 3B, 3C and 3D were used to study the in vitro release of ointments of different specifications according to the above in vitro release determination method. The results are shown in Table 16:
[0232] Table 16
[0233]
[0234] According to Table 16, a trend line is drawn with the square root of time as the abscissa and the amount of drug released per unit area (cumulatively) as the ordinate, such as Figure 6 ; The slope of the trend line is the release rate, as shown in Table 17 below:
[0235] Table 17
[0236] serial number Specification (mg / g) Release rate (slope) 3A 1(0.1%) 113.0133 3B 3(0.3%) 324.4198 3C 10(1.0%) 984.0363 3D 15(1.5%) 1325.1572
[0237] With specification as the horizontal axis and release rate (slope) as the vertical axis, a curve is drawn. Figure 7 , linear regression, square correlation coefficient (R 2 ) is greater than 0.90, indicating that the release rates of different specifications are linear.
[0238] The results showed that as the content of active pharmaceutical ingredients increased, the release amount and release rate of the ointment increased.
[0239] Effect Example 3 Ointment in vitro percutaneous permeability
[0240] Samples 1C, 1D, 3A, 3B, 3C, 3D and 1a were tested for in vitro percutaneous permeability of the ointment.
[0241] The test method is as follows:
[0242] The skin was treated with physiological saline before use and evenly cut and distributed to each specification of preparation (6 samples for each specification). The active ingredient ointment of the drug was applied to the stratum corneum side of the skin using a degreased cotton swab. According to the diameter of the diffusion cell, the amount of drug applied was approximately 0.2 g.
[0243] A Franz diffusion cell with a diameter of 2 cm was used, and 10% ethanol saline was used as the receiving liquid. The volume of the receiving cell was about 7 mL. The treated pig skin was fixed on the Franz diffusion cell, with the stratum corneum facing the supply cell upward and the dermis facing the receiving cell downward. The ointment was evenly applied to the stratum corneum skin, with an application amount of 0.2 g. The receiving cell was filled with degassed receiving liquid. The diffusion cell was placed in a (32±1)℃ constant temperature water bath, and the electromagnetic stirrer was turned on for continuous stirring at a speed of 200 rpm. All the receiving liquid was taken out at 2, 4, 6, 8, 10, and 24 hours, and an equal volume of isothermal receiving liquid was added. The receiving liquid to be tested was stored at 5℃, and the test was terminated at 24 hours, and the skin on each cup was treated.
[0244] Receiving solution treatment: After the in vitro percutaneous permeation test is completed, accurately pipette 200 μL of receiving solution into a 96-well plate, add 200 μL of internal standard solution (50% methanol aqueous solution of diclofenac sodium, 92.76 ng / mL), vortex for 10 min to mix. Centrifuge for 15 min (5°C, 4000g); accurately pipette 200 μL of supernatant into another 96-well plate to obtain the sample to be tested.
[0245] Skin treatment (remaining ointment on the skin surface): After the in vitro percutaneous permeation test is completed, take out the transdermal diffusion cell, observe whether there is obvious ointment on the skin surface, gently absorb the liquid on the skin surface with a rubber-tipped dropper, absorb the remaining ointment liquid on the skin surface as much as possible, transfer to a volumetric flask, and then use a 1mL pipette to transfer 2mL of methanol to the supply cell, and gently scrape the skin surface with a small spoon to dissolve the remaining drug on the skin surface in methanol as much as possible, and transfer the washing liquid to the above volumetric flask. Repeat the above operation 6 times, sonicate for 15 minutes, and then cool and make up the volume with methanol. The ointment collection liquid is stored at 5°C. Accurately aspirate 10μL of the ointment collection liquid analysis sample, add 990μL of blank matrix to dilute, and vortex for 3min to mix. Pipette more than 200μL of the analysis sample into a 1.5mL EP tube, add 600μL of internal standard solution (50% methanol aqueous solution of diclofenac sodium, 92.76ng / mL), and vortex for 10min to mix. Centrifuge for 5 min (5°C, 12000 rpm / min); accurately pipette 200 μL of the supernatant into a 96-well plate to obtain the sample to be tested.
[0246] Skin treatment (skin extract): After the treatment of the remaining ointment on the skin surface, remove the skin, wash off the ointment on the skin surface, and use filter paper to absorb the residual solvent on the skin surface. Use scissors to cut off the outer skin that is not directly in contact with the ointment, leaving only the skin of the same size as the pool opening (i.e. about 3.14cm 2 ), weigh the treated skin, seal it in an EP tube and store it. Cut the skin into pieces, freeze it in liquid nitrogen for more than 1 hour, and grind it into powder in a freezer grinder. Transfer the grinding ball directly to a 50mL EP tube, transfer the powder to the above 50mL EP tube in small amounts and multiple times with 25mL of methanol, sonicate, shake well, and pipette 1mL into a 1.5mL EP tube. The obtained skin extract is sealed and stored at 5°C. Accurately pipette 200μL of skin extract into a 1.5mL EP tube, add 200μL of internal standard solution (50% methanol aqueous solution of diclofenac sodium, 92.76ng / mL), and vortex for 10min to mix. Centrifuge for 5min (5°C, 12000rpm / min); accurately pipette 200μL of supernatant into a 96-well plate to obtain the sample to be tested.
[0247] The concentrations of active pharmaceutical ingredients in the receiving solution, the remaining ointment on the skin surface, and the skin extract were determined by LC-MS / MS. The cumulative permeation amount and the skin retention amount were calculated.
[0248] The results of the transdermal test are shown in Table 18 below:
[0249] Table 18
[0250]
[0251] Analysis of results: It can be seen from the in vitro permeation results of samples 1a, 1C and 1D that as the mass ratio of polyethylene glycol 400 / diethylene glycol monoethyl ether and the mass ratio of polyethylene glycol 3350 / diethylene glycol monoethyl ether decrease, the unit skin retention increases. Comparing the results of samples 3A, 3B, 3C and 3D, it can be seen that the skin retention of the ointment is correlated to the drug loading, and the skin retention per unit area increases with the increase of the drug loading. The retention amount / penetration amount of the composition of the present invention is much larger, indicating that the composition of the present invention enters the blood less and has a small systemic risk.
[0252] Effect Example 4 Stability Study Results
[0253] Stability studies were performed on samples 3B, 3C and 3D.
[0254] The analysis method is as follows:
[0255] (1) Shape: The shape of the ointment was checked visually.
[0256] (2) pH value: The ointment was diluted 10 times with purified water that had been freshly boiled and cooled to room temperature. After dispersion by shaking, the pH value was measured using a pH meter.
[0257] (3) Related substances (impurities, types are as shown in Table 19 below): Determine related substances according to high performance liquid chromatography (Chinese Pharmacopoeia 2020 Edition Part IV General Rules 0512). The method for determining related substances is as follows: the chromatographic column is a Waters Xselect Hss T3C18 column (4.6*150mm 3.5μm), with a 10mM ammonium acetate aqueous solution (precisely pipette 0.77g of ammonium acetate into 1000mL of pure water, mix well, and degas) as mobile phase A; acetonitrile is used as mobile phase B; gradient elution is performed as shown in Table 20 below; the flow rate is 1.0mL / min; the column temperature is 15°C; the detection wavelength is 254nm; the running time is 45min; the needle washing solution is 50% acetonitrile aqueous solution.
[0258] Table 19
[0259]
[0260]
[0261] Table 20
[0262] Time (min) Mobile phase A (%) Mobile phase B (%) 0 90 10 5 70 30 25 60 40 35 10 90 40 10 90 40.1 90 10 45 90 10
[0263] (3) Content: Determine the content according to high performance liquid chromatography (Chinese Pharmacopoeia 2020 Edition Part IV General Rules 0512). The content determination method is as follows: use 0.02mol / L disodium hydrogen phosphate dodecahydrate buffer (weigh 7.20g disodium hydrogen phosphate dodecahydrate, add 1000mL water to dissolve, adjust the pH to 7.80±0.05 with phosphoric acid, and filter with 0.45μm water filter membrane to obtain)-acetonitrile (60:40) as the mobile phase, isocratic elution; column temperature is 30℃; detection wavelength is 255nm, flow rate is 1.0mL per minute, and injection volume is 10μL. The content detection method is also applicable to the content detection of butylated hydroxytoluene.
[0264] (4) Viscosity: The viscosity was measured using an American Brookfield viscometer.
[0265] (5) Microscopy: Take a clean glass slide, apply an appropriate amount (about 0.01 g each time) of the ointment on the slide, cover it with a cover slip, press the cover slip gently, and first observe the ointment under a microscopic microscope under the conditions of 10X eyepiece, 40X objective lens, and 300° polarized light.
[0266] The results are as follows:
[0267] A. High temperature 50℃, light ≥1.2×10 6 The results of the 30-day stability study under lux·hr conditions are shown in Table 21.
[0268] Table 21
[0269]
[0270]
[0271]
[0272] Note: “ND” means below the reporting limit of 0.05% or not detected, and “-” means not applicable.
[0273] B. The results of the 3-month stability study under accelerated conditions (40°C, 75% RH) are shown in Table 22.
[0274] Table 22
[0275]
[0276]
[0277] C. The results of the 3-month stability study under long-term conditions (25°C, 60% RH) are shown in Table 23.
[0278] Table 23
[0279]
[0280]
[0281] D. During use (32°C, 75% RH), the results of a 2-month stability study are shown in Table 24.
[0282] Table 24
[0283]
[0284]
[0285]
[0286] From the results of Tables 21 to 24, it can be seen that the properties, pH, content, related substances and viscosity of the pharmaceutical compositions of different specifications are not significantly changed when compared with the results of 0 day under the influencing factors of 30 days, accelerated and long-term conditions for 3 months, and the stability during use is investigated, and the results are good. In summary, the pharmaceutical composition of the present invention has good stability when used in preparations.
[0287] Effect Example 5 Pharmacokinetic (PK) Study Results
[0288] Experimental methods:
[0289] Twenty-four (12 / sex) male and female Bama miniature pigs were divided into five groups. The ointment was applied to 10% of the animal's estimated body surface area.
[0290] The ointment of sample 2A and sample 2B was applied to the skin once to the animals in group 1 and group 2, respectively, and plasma, stratum corneum, epidermis and dermis samples were collected before administration (0, plasma only) and 0.5, 1, 4, 8, 12 and 24 hours after administration.
[0291] The ointment of sample 2B was applied to the skin of the animals in group 3 once a day for 7 consecutive days. Plasma samples were collected before administration (0) and 0.5, 1, 4, 8, 12 and 24 hours after administration on days 1 and 7, and plasma samples were collected before administration (0) on days 3, 4, 5 and 6; stratum corneum, epidermis and dermis samples were collected 0.5, 1, 4, 8, 12 and 24 hours after administration on day 7.
[0292] The ointment of sample 2a was applied to the skin once to the animals in group 4, and plasma, stratum corneum, epidermis, dermis and subcutaneous tissue samples were collected before administration (0, plasma only) and 0.5, 1, 4, 8, 12 and 24 hours after administration.
[0293] Animals in Group 5 received a single skin application of sample 3a (at 6 mg / mL at 25 μL / m 2Administration), blood and skin samples were collected before administration (0) and 0.5, 1, 3 and 6 hours after administration. Blood was obtained by venipuncture and collected in tubes containing sodium heparin as an anticoagulant. The exposed skin was washed with soap and water, and then the skin samples were collected. On the administered skin, punch biopsies from the epidermis to the muscle layer were obtained at each time point. The epidermis, dermis, subcutaneous tissue and subcutaneous muscle were quickly separated, weighed and frozen in dry ice. The epidermis and dermis were homogenized in normal saline at 1:3 (w / v). The homogenized samples were extracted with three volumes of acetonitrile and quantified against a standard curve using an LC-MS / MS system.
[0294] High-performance liquid chromatography-ultraviolet detection (LC-MS / MS) was used to determine the concentrations of active pharmaceutical ingredients in plasma, stratum corneum, epidermis, and dermis samples.
[0295] Table 25
[0296]
[0297]
[0298] Note: “h*ng / mL” is the unit corresponding to plasma, and “ng*h / g” is the unit corresponding to skin tissue.
[0299] The results of skin application showed that: comparing the results of 2A and 2B, it was shown that the AUC of different skin layers was positively correlated with the dosage. 0-last The higher the concentration, the more active ingredients of the drug can effectively penetrate the stratum corneum and stay in the effective treatment area. The plasma concentration of all active ingredients of the drug is lower than the lower limit of quantification, indicating that the active ingredients of the drug enter the blood less. In addition, 12 μg / cm2 was applied to the skin once a day for 7 consecutive days. 2 After application of ointment, the exposure in the stratum corneum, epidermis, and dermis of males and females (AUC 0-last With C max ) remained basically unchanged, indicating that there was no accumulation of the active ingredients of the drug after administration.
[0300] Compared with the composition of tofacitinib (sample 2a) and the aqueous composition (sample 3a), after application of the composition of the active pharmaceutical ingredient of the present invention, the retention amount of the active pharmaceutical ingredient per unit dose in the epidermis and dermis is much greater than that of sample 2a and sample 3a, indicating that the agent of the present invention can better penetrate the stratum corneum to reach the effective site and has better permeability.
[0301] Effect Example 6 Stability Study Results
[0302] The stability of sample 3D was studied. The analysis method is as follows: Example 4.
[0303] The results of the 6-12 month stability study of sample 3D under long-term conditions (25°C, 60% RH) are shown in Table 26.
[0304] Table 26
[0305]
[0306]
[0307] From the results in Table 26, it can be seen that the pharmaceutical composition of sample 3D obtained in Example 3 has no significant changes in properties, pH, content, related substances and viscosity after being placed under the influencing factors for 6 months, 9 months and 12 months, and the stability during use is investigated, and the results are good. In summary, the pharmaceutical composition of the present invention has good stability when used in preparations.
Claims
1. A pharmaceutical composition, characterized in that The pharmaceutical composition comprises a pharmaceutical active ingredient, diethylene glycol monoethyl ether and polyethylene glycol 400; the pharmaceutical composition does not contain water; Wherein, the mass ratio of the diethylene glycol monoethyl ether to the polyethylene glycol 400 is 1:(0.5-4.0); the active pharmaceutical ingredient has the structural formula (I):
2. The pharmaceutical composition according to claim 1, characterized in that The dosage of the active pharmaceutical ingredient is 0.001% to 10%, for example, 0.1%, 0.3%, 0.6%, 1.0%, 1.2%, 1.5% or 2.0%, where % refers to the mass percentage of the active pharmaceutical ingredient in the pharmaceutical composition; And / or, the amount of diethylene glycol monoethyl ether is 15-40%, for example 20.0%, 23.0% or 33.8%, % refers to the mass percentage of diethylene glycol monoethyl ether in the pharmaceutical composition; And / or, the amount of polyethylene glycol 400 is 30-55%, for example, 30.4%, 38.8%, 45.3%, 52.5% or 52.9%, % refers to the mass percentage of polyethylene glycol 400 in the pharmaceutical composition; and / or, the mass ratio of the pharmaceutically active ingredient to the diethylene glycol monoethyl ether is 1:(10.0-250.0), for example, 1:13.33, 1:15.33, 1:16.67, 1:16.90, 1:20, 1:23, 1:33.33, 1:66.67, 1:76.67, 1:200 or 1:230; And / or, the mass ratio of the diethylene glycol monoethyl ether to the polyethylene glycol 400 is 1:(0.5-3.0), for example, 1:0.90, 1:1.94, 1:1.97, 1:2.63 or 2.
65.
3. The pharmaceutical composition according to claim 1 or 2, characterized in that The pharmaceutical composition also includes polyethylene glycol 3350; And / or, the pharmaceutical composition further comprises one or more of an antioxidant, a preservative, a hardener and a humectant.
4. The pharmaceutical composition according to claim 3, characterized in that When the pharmaceutical composition includes polyethylene glycol 3350, the amount of polyethylene glycol 3350 is 25.0-50%, preferably 25.0-45.0%, for example 25.8%, 26.3%, 26.5%, 27%, 27.2%, 30%, 30.5%, 31.2%, 31.4%, 33.8% or 40%; And / or, when the pharmaceutical composition includes polyethylene glycol 3350, the mass ratio of the diethylene glycol monoethyl ether to the polyethylene glycol 3350 is 1:(0.5-3.6), preferably 1:(0.5-3.0), for example 1:1.00, 1:1.29, 1:1.30, 1:1.32, 1:1.33, 1:1.35, 1:1.36, 1:1.37 or 1:2.00; And / or, the antioxidant is an aromatic amine antioxidant, such as butylated hydroxytoluene; And / or, the antioxidant is used in an amount of 0.05-0.2%, for example 0.1%; and / or, the preservative is one or more of methylparaben, sorbic acid and salts thereof, such as methylparaben; and / or, the amount of the preservative is 0.05-0.2%, for example 0.1%; and / or, the hardener is one or more of paraffin, beeswax, cetostearyl alcohol, white vaseline and glyceryl mono- and distearate; and / or, the amount of the hardener is 5-40%, for example 9.8%, 22.1%, 30.65% or 37.6%; and / or, the moisturizing agent is one or more of glycerin, light liquid paraffin, soybean oil, medium chain triglycerides, sodium hyaluronate, urea, propylene glycol, butylene glycol, panthenol, sodium pyrrolidone carboxylate and trehalose, preferably propylene glycol; And / or, the amount of the moisturizer is 2-80%, for example, 5.0%, 9.0%, 20.0%, 37.5% or 77.5%.
5. The pharmaceutical composition according to claim 3, characterized in that The pharmaceutical composition comprises the pharmaceutical active ingredient, diethylene glycol monoethyl ether, polyethylene glycol 400 and polyethylene glycol 3350; the pharmaceutical composition does not include water; Wherein, the mass ratio of the diethylene glycol monoethyl ether to the polyethylene glycol 400 is 1:(0.5-4.0); the mass ratio of the diethylene glycol monoethyl ether to the polyethylene glycol 3350 is 1:(0.5-3.6); Preferably, the pharmaceutical composition comprises the pharmaceutical active ingredient, diethylene glycol monoethyl ether, polyethylene glycol 400 and polyethylene glycol 3350; the pharmaceutical composition does not include water; Wherein, the mass ratio of the diethylene glycol monoethyl ether to the polyethylene glycol 400 is 1:(0.5-3.0); the mass ratio of the diethylene glycol monoethyl ether to the polyethylene glycol 3350 is 1:(0.5-3.0); More preferably, the pharmaceutical composition comprises, by weight percentage: Further more preferably, In terms of weight percentage, the pharmaceutical composition comprises:
6. An external preparation, characterized in that It comprises the pharmaceutical composition according to any one of claims 1 to 5.
7. The external preparation according to claim 6, characterized in that The external preparation is a liquid preparation or a semisolid preparation; The liquid preparation is preferably a liniment or a tincture; the semisolid preparation is preferably a cream, an organogel, an ointment or a paste; Preferably, the ointment comprises, by weight percentage: More preferably, The ointment formulation comprises, by weight percentage: or, The ointment formulation comprises, by weight percentage: or, The ointment formulation comprises, by weight percentage: or, According to weight percentage, the ointment comprises: or, According to weight percentage, the ointment comprises: Further more preferably, The ointment formulation comprises, by weight percentage: or, The ointment formulation comprises, by weight percentage: or, The ointment formulation comprises, by weight percentage: or, The ointment formulation comprises, by weight percentage: Diethylene glycol monoethyl ether 33.8% Polyethylene glycol 400 30.4% Polyethylene glycol 3350 33.8%; or, The ointment formulation comprises, by weight percentage: Active pharmaceutical ingredient 0.1% Diethylene glycol monoethyl ether 20.0% Polyethylene glycol 400 52.5% Polyethylene glycol 3350 27.2% Butylated hydroxytoluene 0.1% Methylparaben 0.1%; or, The ointment formulation comprises, by weight percentage: Active pharmaceutical ingredient 0.3% Diethylene glycol monoethyl ether 20.0% Polyethylene glycol 400 52.5% Polyethylene glycol 3350 27.0% Butylated hydroxytoluene 0.1% Methylparaben 0.1%; or, The ointment formulation comprises, by weight percentage: Active pharmaceutical ingredient 1.0% Diethylene glycol monoethyl ether 20.0% Polyethylene glycol 400 52.5% Polyethylene glycol 3350 26.3% Butylated hydroxytoluene 0.1% Methylparaben 0.1%; or, The ointment formulation comprises, by weight percentage: Active ingredient 1.5% Diethylene glycol monoethyl ether 20.0% or, The ointment formulation comprises, by weight percentage: or, More preferably, the ointment comprises, by weight percentage: More preferably, the ointment comprises, by weight percentage: or, The ointment formulation comprises, by weight percentage: Active ingredient 1.5% Diethylene glycol monoethyl ether 23.0% Polyethylene glycol 400 45.3% Polyethylene glycol 3350 30.0% Butylated hydroxytoluene 0.1% Methylparaben 0.1%.
8. A method for preparing the pharmaceutical composition according to any one of claims 1 to 5, characterized in that: It includes the following steps: (1) Preparation of API solution: Mix the active ingredient, diethylene glycol monoethyl ether and polyethylene glycol 400 at 50-80°C until dissolved; (2) Preparation of matrix solution: Heat polyethylene glycol 3350 at 50-80°C until it melts; (3) Preparation of ointment: Mix the API solution and the base solution under stirring conditions.
9. The method for preparing the pharmaceutical composition according to claim 8, characterized in that: In step (1), the mixing temperature is 50°C or 80°C; And / or, in step (2), the raw materials further include one or more of an antioxidant, a preservative, a hardener and a humectant; And / or, in step (2), the raw material further comprises diethylene glycol monoethyl ether; preferably, when the raw material in step (2) comprises diethylene glycol monoethyl ether, the amount of diethylene glycol monoethyl ether in step (1) is 2 / 3 of the prescribed amount, and the amount of diethylene glycol monoethyl ether in step (2) is 1 / 3 of the prescribed amount; And / or, in step (2), the heating temperature is 50° C. or 80° C.; And / or, in step (3), the stirring speed is 315 rpm; And / or, in step (3), the stirring time is 10 to 15 minutes; And / or, in step (3), the mixing temperature is 50-60°C; And / or, in step (3), after the mixing is completed, a cooling operation is also included.
10. Use of the pharmaceutical composition according to any one of claims 1 to 5, or the external preparation according to claim 6 or 7, in the preparation of a drug for treating autoimmune diseases; Preferably, the autoimmune disease is arthritis, rheumatoid arthritis, psoriasis, psoriasis, osteoarthritis, regional suppurative disease, ankylosing spondylitis, autoimmune eye disease, dry eye, atopic dermatitis, contact dermatitis, systemic lupus erythematosus or alopecia areata.
Citation Information
Cited By
Extraction method and detection method of ripdicaine medicine in skin
CN120121380A
